Bundles of the weight-loss drug Wegovy from the pharmaceutical business Novo Nordisk push the sales counter in a Danish drug store.
Stefan Trumpf|Photo Alliance|Getty Images
The European Medicines Company stated Monday it would carry out an evaluation into a variety of substance abuse to deal with weight problems and diabetes after it was reported some clients experienced ideas of suicide or self-harm.
In a declaration, the regulator stated its security committee, or PRAC, was “presently assessing the threat of self-destructive ideas and ideas of self-harm in clients who utilized a semaglutide– or liraglutide– including medication for weight-loss.”
” The evaluation is being performed in the context of a signal treatment raised by the Icelandic Medicines Company following 3 case reports,” the EMA stated. “A signal is details on a brand-new or recognized negative occasion that is possibly triggered by a medication which warrants even more examination.”
The EMA stated the case reports “consisted of 2 cases of self-destructive ideas, one following making use of Saxenda and one after Ozempic. One extra case reported ideas of self-injury with Saxenda.”
” The semaglutide-containing medication Wegovy and the liraglutide-containing medication Saxenda are authorised for weight-loss, together with diet plan and exercise,” the EMA stated.
Ozempic is utilized to deal with type 2 diabetes, and its active component is semaglutide. All drugs are produced by Danish company Novo Nordisk
Shares of the business were somewhat greater on Monday afternoon, paring earlier losses.
” Self-destructive behaviour is not presently noted as a negative effects in the EU item details of these medications,” the EMA stated. “The PRAC will think about whether the evaluation ought to be encompassed likewise consist of other medications of the exact same class (‘ GLP-1 receptor agonist’).”
In a declaration sent out to CNBC, Novo Nordisk stated, “Client security is a leading concern for Novo Nordisk, and we take all reports about negative occasions from usage of our medications really seriously.”
” GLP-1 receptor agonists have actually been utilized to deal with type 2 diabetes for more than 15 years and for treatment of weight problems for 8 years, consisting of Novo Nordisk items such as semaglutide and liraglutide that have actually been on the marketplace for more than ten years,” it included.
” The security information gathered from big scientific trial programs and post marketing monitoring have actually not shown a causal association in between semaglutide or liraglutide and self-destructive and self-harming ideas.”
Business stated that it was “constantly carrying out monitoring of the information from continuous scientific trials and real-world usage of its items and collaborates carefully with the authorities to make sure client security and sufficient details to health care specialists.”
” EMA constantly keeps an eye on for security signals therefore does Novo Nordisk,” it stated. “Novo Nordisk stays positive in the advantage threat profile of the items and stays dedicated to making sure client security.”